SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer

## Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment

SymBio Pharmaceuticals Limited (the "Company") hereby announces the monthly exercise status for October 2025 of the 58th Stock Acquisition Rights, which were allotted to CVI Investments, Inc. and issued on June 1, 2022, and the 65th Stock Acquisition Rights, which were allotted to EVO FUND and issued on August 12, 2025 (collectively or individually referred to as the "Stock Acquisition Rights").

The Company is disclosing monthly exercise status for the 58th Stock Acquisition Rights, as these rights are now deemed to fall under MSCBs, etc. as defined in Article 410 of the Securities Listing Regulations established by the Tokyo Stock Exchange, following the issuance of the 65th through 67th Stock Acquisition Rights on August 12, 2025.

The exercise prices of the 66th and 67th Stock Acquisition Rights issued to EVO FUND on August 12, 2025, have been revised in line with the exercise price of the 65th Stock Acquisition Rights, as noted in "6. Exercise Status in the Relevant Month" below. However, under the purchase agreement with EVO FUND, the 66th Stock Acquisition Rights cannot, in principle, be exercised until August 13, 2026, and the 67th Stock Acquisition Rights until August 13, 2027. Therefore, the Company is omitting the disclosure of their monthly exercise status.

1.	Name of Stock Acquisition Rights	(1) SymBio Pharmaceuticals	(2) SymBio Pharmaceuticals	
		Limited's 65th Stock	Limited's 58th Stock	
		Acquisition Rights	Acquisition Rights	
	Number of Shares			
2.	Delivered in the Relevant	2,600,000 shares	0 shares	
	Month			
	Number of Stock			
	Acquisition Rights	26,000 rights	0 rights	
,	Exercised in the Relevant	(Ratio to total number of Stock	(Ratio to total number of Stock	
3.	Month, and Ratio of	Acquisition Rights issued 200,000:	Acquisition Rights issued	
	Exercised to Total Issued	13.0%)	[20,000]: 0%)	
	Stock Acquisition Rights			
	Number of Unexercised			
	Stock Acquisition Rights as	400 400 : 14	00.000 : 14	
4.	of the end of the previous	168,400 rights	20,000 rights	
	month			
	Number of Unexercised			
5.	Stock Acquisition Rights as	440 400	20,000 rights	
	of the End of the Relevant	142,400 rights		
	Month			

<sup>\*</sup> The ratio of exercised to total issued Stock Acquisition Rights is rounded to one decimal place.

#### 6. Exercise Status in the Relevant Month

### (1) SymBio Pharmaceuticals Limited's 65th Stock Acquisition Rights

	Number of Sh	ares Delivered	Exercise Price	Number of Stock
Exercise Date	Newly Issued	Transferred		Acquisition Rights
	Shares	Treasury Shares	(Yen)	Exercised (Rights)
October 1 (Wed)	-	-	135	-
October 2 (Thu)	-	-	135	-
October 3 (Fri)	250,000	-	131	2,500
October 6 (Mon)	500,000	-	131	5,000
October 7 (Tue)	50,000	-	132	500
October 8 (Wed)	-	-	132	-
October 9 (Thu)	50,000	-	131	500
October 10 (Fri)	-	-	131	-
October 14(Tue)	-	-	129	-
October 15 (Wed)	-	-	129	-
October 16(Thu)	50,000	- 129		500
October 17 (Fri)	-	-	129	-
October 20 (Mon)	300,000	-	125	3,000
October 21 (Tue)	300,000	-	125	3,000
October 22 (Wed)	400,000	-	123	4,000
October 23 (Thu)	100,000	-	123	1,000
October 24 (Fri)	ctober 24 (Fri) 50,000 -		123 500	
October 27 (Mon)	50,000	-	123	500
October 28 (Tue)	50,000	-	123	500
October 29 (Wed)	-	-	123	-
October 30 (Thu)	50,000	-	117	500
October 31 (Fri)	400,000	-	117	4,000

<sup>\*</sup> Number of shares issued as of the end of the previous month: 52,041,080 shares (including 90,965 treasury shares)

### (2) SymBio Pharmaceuticals Limited's 58th Stock Acquisition Rights

	Number of Shares Delivered		Eversies Pries	Number of Stock
Exercise Date	Newly Issued	Transferred	Exercise Price	Acquisition Rights
	Shares	Treasury Shares	(Yen)	Exercised (Rights)
October 1 (Wed)	-	-	135	-
October 2 (Thu)	-	-	135	-
October 3 (Fri)	-	-	131	-
October 6 (Mon)	131		-	
October 7 (Tue)	-	131		-
October 8 (Wed)	-	-	131	-
October 9 (Thu)	-	-	131	-
October 10 (Fri)	-	- 131		-
October 14(Tue)	-	-	129	-
October 15 (Wed)	-	-	129	-
October 16(Thu)	-	-	129	-
October 17 (Fri)	-	-	129	-

October 20 (Mon)	-	-	125	-
October 21 (Tue)	-	-	125	-
October 22 (Wed)		123	-	
October 23 (Thu)	-	-	123	-
October 24 (Fri)	-	-	123	-
October 27 (Mon)	-	-	123	-
October 28 (Tue)	-	-	123	-
October 29 (Wed)	-	-	123	-
October 30 (Thu)			117	-
October 31 (Fri)			117	-

<sup>\*</sup> Number of shares issued as of the end of the previous month: 52,041,080 shares (including 90,965 treasury shares).

# 7. Status of Exercise Restrictions (Status of Compliance with Exercise Restrictions under Article 434 of the Listing Regulations)

(i)	Total Number of Shares	(ii)	Number of Listed Shares	(iii)	Exercise Ratio Subject to
	Delivered (All Series		as of Payment Date of		Exercise Restrictions
Combined)		Issuance		((i) / (ii))	
	2,600,000 shares		48,855,455 shares		5.3%

<sup>\*</sup> The exercise ratio subject to exercise restrictions is rounded to one decimal place.

For further details regarding these Stock Acquisition Rights, please refer to the "Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party allotment" announced on May 16, 2022, the "Notice Concerning the Treatment of the 58th Stock Acquisition Rights in Light of the Issuance of the 65th to 67th Stock Acquisition Rights" announced on July 22, 2025, and the "Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights" announced on July 22, 2025.